Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc demonstrated impressive financial performance with a 32% year-over-year revenue growth in 4Q24, reaching $86.6 million, and an overall annual revenue growth of 19% in 2024, with projections of 17% growth for 2025. The company is experiencing increasing testing volumes, evidenced by a 14% rise in volume from 4Q23 to 4Q24, and is strategically focused on achieving a long-term revenue target of $500 million by 2027. Key growth initiatives, including expanding payer coverage and enhancing operational excellence, position CareDx for sustained momentum in the precision medicine sector, particularly within the transplant community.

Bears say

CareDx Inc faces significant financial risks that contribute to a negative outlook for its stock. Key concerns include the potential inability to secure adequate reimbursement for its testing services, competition from superior tests developed by rivals, and integration challenges from acquisitions that could disrupt business operations. Additionally, the company's EBITDA guidance fell short of expectations, further highlighting uncertainties around the commercial success of its products and the broader implications of compliance with evolving healthcare policies.

CareDx (CDNA) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 11 analysts, CareDx (CDNA) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.